Redeye comments on Annexin Pharmaceuticals’ approval to start the phase IIa study in diabetic retino...
DT’s Q2 earnings were softer than estimated and disappointingly Q3 results too are about to decline,...
Redeye notes that BeammWave surprised by posting net sales of SEK1.
Redeye provides an update following Optomed’s Q2 2025 report.
CapMan's Q2 2025 results were largely in line with our expectations, with fee income declining sligh...
Prospekterings- och gruvutvecklingsbolaget Bluelake Mineral fick planförslag och reguleringsplan för...
Suominen’s Q2 revenue dropped steeply as the tariff situation caused volatility in the US supply cha...
Adj. EBIT -29% vs FactSet consensus; FX adj sales -11% y-o-y Estimates to come down 8-10% on slower ...
Redeye provides an initial take following the release of Optomed’s Q2 2025 report.
Redeye notes that BeammWave’s Q2 2025 report delivered a surprise, with the company posting net sale...
CapMan’s Q2 results were decent, but the operating profit fell below expectations largely due to low...
Etteplan’s H1 was disappointing, with the escalation of the trade war causing demand to weaken furth...
Redeye comments on G5’s Q2-results where results were weaker than expected, partly driven by USD/SEK...
Redeye updates on EG7 ahead of Q2-results (due 15 August) where we expect solid YoY growth driven by...
Cargo tonnes and the number of passengers increased y/y in Q2.
New full year guidance for adjusted EBITDA in core businesses’ is EUR 16–20m in 2025 (previously EUR...
There were no surprises in Etteplan’s Q2 figures, since the company earlier issued a profit warning ...
Redeye comments on Faron’s updated data from the Phase I/II BEXMAB trial in frontline high-risk MDS,...
Redeye updates on W5 Solutions after Q2-results which saw weaker-than-expected profitability while a...
Raute reports Q2 results on Aug 12. This year will set another earnings record, while the focus now ...
